SCHEMBL5715212

SCHEMBL5715212

Cc1ccnc(CCc2ccc(OC(=O)N3CCN(c4ccc(C(=O)O)cn4)CC3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.43
PANK3 Q9H999 1/20 0.43
ME2 P23368 3/20 0.42
ME1 P48163 3/20 0.42
ME3 Q16798 3/20 0.42
SMO Q99835 1/20 0.40
OGA O60502 1/20 0.40
AOC3 Q16853 3/20 0.40
P2RY12 Q9H244 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HPGD P15428 1/20 0.39
GPR119 Q8TDV5 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
WNT3A P56704 1/20 0.38
HDAC1 Q13547 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714845 0.92 HRH3 (0.46) HRH3PANK3ME2ME1ME3
SCHEMBL5714994 0.91 PANK3 (0.46) HRH3PANK3ME2ME1ME3
SCHEMBL5715073 0.89 PANK3 (0.43) HRH3PANK3ME2ME1ME3
SCHEMBL5714673 0.88 ME2 (0.45) HRH3PANK3ME2ME1ME3
SCHEMBL5715391 0.88 PANK3 (0.46) PANK3ME2ME1ME3AOC3
SCHEMBL5714320 0.87 AOC3 (0.47) HRH3PANK3ME2ME1ME3
SCHEMBL5714884 0.87 KDM4E (0.43) HRH3AOC3KDM4EALDH1A1TSHR
SCHEMBL5714351 0.86 SMN1; SMN2 (0.58) HRH3SMN1; SMN2HPGDKDM4EALDH1A1
SCHEMBL5714630 0.85 KDM4E (0.52) SMN1; SMN2HPGDKDM4EALDH1A1LMNA
SCHEMBL5715492 0.84 DRD2 (0.42) AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC HRH3 1098/4885PANK3 1247/4885ME2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.